ライフサイエンスコーパス: study group

1 ed to receive stents (control group) or not (study group).

2 vents occurred in 2% of the patients in each study group).

3 eview and examination of multimodal imaging (study group).

4 trol group and 18.9%, 13.2%, and 3.8% in the study group).

5 n respective resistance-determining regions (study group).

6 I: 2.1, 14.5 nmol/L; P < 0.009, I(2) = 0%; 4 study groups).

7 I: -2.3, 6.0 nmol/L; P < 0.38, I(2) = 37%; 7 study groups).

8 ears; 245 boys [63%]), 382 (96%) in the main study group.

9 ely to SIgA-deficient airways, regardless of study group.

10 ether psychological trajectories differed by study group.

11 ary outcome was time to diabetes in the main study group.

12 ced risk of HIV acquisition, irrespective of study group.

13 lapse followed by liver biopsy comprised the study group.

14 on and multiple covariates, including pH and study group.

15 ggesting some natural exposure to HBV in the study group.

16 were severe, and the rate did not differ by study group.

17 dex varied during the study period in either study group.

18 r Research and Treatment of Cancer / Mycosis Study Group.

19 the findings for all patients rather than by study group.

20 he study; 86 in the sham group and 84 in the study group.

21 cific carriage rates at age 9 months in each study group.

22 low overall prevalence of malignancy in our study group.

23 t and diet contributed to PR exposure in our study group.

24 not different in ALS compared with any other study group.

25 Leukemia-Berlin-Frankfurt-Munster (AML-BFM) study group.

26 erious adverse events were noted between the study groups.

27 vely, were significantly different among the study groups.

28 did not differ significantly between the two study groups.

29 ltaCF values in the investigated prospective study groups.

30 f serious adverse events were similar in the study groups.

31 d in-hospital mortality were similar between study groups.

32 method was used to balance covariates across study groups.

33 sed to compare breast-milk VDA between the 3 study groups.

34 orted quality of life was similar in the two study groups.

35 justed differences in rates of change across study groups.

36 tion doses absorbed were similar between the study groups.

37 ter treatment with purified albumin from the study groups.

38 on in induced sputum cells obtained from the study groups.

39 Stroke rates were equal in the study groups.

40 tes of adverse events were similar among the study groups.

41 method was used to balance covariates across study groups.

42 Adverse events were balanced between the study groups.

43 ignificant difference between the predefined study groups.

44 nts and low use with steady partners in both study groups.

45 eight, and parity) were similar between both study groups.

46 models were used to compare outcomes between study groups.

47 ndom numbers used to assign matched pairs to study groups.

48 ze of inguinal hernias were similar in the 3 study groups.

49 rious adverse events were similar in the two study groups.

50 ine characteristics were similar between the study groups.

51 ne and chemokine expression in our different study groups.

52 Thirty-seven patients were included in both study groups.

53 intment remained stable over time in the two study groups.

54 response or need for analgesics between the study groups.

55 13, we randomly assigned 1000 infants to our study groups.

56 e- and post-treatment measurements among the study groups.

57 f women who participated in screening in the study groups.

58 ion did not significantly differ between the study groups.

59 es of a continuous variable across different study groups.

60 utation was done to allocate clusters to the study groups.

61 n score, and cost-effectiveness between both study groups.

62 med between NE, MMP-8, MMP-9, and MPO within study groups.

63 s well as insulin resistance among the eight studied groups.

64 mandible were enrolled in this observational study (group 1 = 50 patients with thin biotype; group 2

65 Study groups 1-3 received ALVAC-HIV+AIDSVAX B/E, AIDSVAX

66 Two groups were analyzed for this pilot study: Group 1 was composed of IRD two with autosomal do

67 Thirty-three patients were assigned to study groups: 1) test: DGG + OT; or 2) control group: DG

68 ery did not differ significantly between the study groups (-17.9 in the decompression-alone group and

69 randomized International Extranodal Lymphoma Study Group 19 (IELSG-19) trial.

70 le procedure was significantly higher in the study group (19/20, 95%) than in the control group (25/4

71 rment at birth was also less frequent in the study group (2.2% vs 17.4%; P = .012).

72 6%), 420 of whom were randomly assigned to a study group (209 to the radiotherapy group and 211 to no

73 Across all study groups, 25 grade 3 or worse surgery-related compli

74 (2) reported patients with MCI as a primary study group, (3) reported depression or depressive sympt

75 rt of study treatment was similar in the two study groups: 30 children died in the co-trimoxazole gro

76 The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international rando

77 ed phase 2 International Extranodal Lymphoma Study Group-32 (IELSG32) trial, HIV-negative patients (a

78 Finding alternatives to intensively studied group 4 d(0) and late-transition-metal catalysts

79 rious adverse events were similar in the two study groups (47% in the ixazomib group and 49% in the p

80 rvival rate was lower in candidates from the study group (52.2%) compared with comparison group (75.5

81 Of the 87 LT recipients (study group), 58 (66.7%) had none or less than 50% steno

82 Within the study group, 60 of these cats had a euthyroid (n = 23) o

83 8 phase 1 [P1] and 1536 phase 2 [P2]) in the study group; 64% (1499) were male, and the median age wa

84 mplexes equivalent to their much more widely studied group 7 analogues.

85 nosis of infection was established by the IE Study Group according to the clinical, echocardiographic

86 sure was the Alzheimer's Disease Cooperative Study Group Activities of Daily Living Scale (ADCS ADL);

87 sure was the Alzheimer's Disease Cooperative Study Group Activities of Daily Living Scale (ADCS ADL);

88 to-treat population, but were similar across study groups among the per-protocol population.

89 24 hours and >300 mg/24 hours, respectively) study group and 18 healthy volunteers.

90 of the complication was 4.87% (4/82) in the study group and 20.23% (17/84) in the placebo group; thi

91 Among 61 primary culture isolates (25 study group and 36 control group), SMOR described 66 (49

92 Of 1141 patients (763 in the study group and 378 in the control group), 664 (58%) had

93 d and fourteen patients were included in the study group and 789 in the control group.

94 sixty-six patients were included; 82 in the study group and 84 in the placebo group.

95 nd point was achieved in 164 patients in the study group and 85 patients in the control group.

96 Six sites of the Hellenic Sepsis Study Group and at Jena University Hospital.

97 and clinical findings was determined in the study group and in an age- and sex-matched control group

98 Interaction analyses controlling for study group and maternal atopy confirmed that maternal p

99 ed glomerular filtration rate between the RF study group and PF controls.

100 Members of the International PSC Study Group and radiologists from North America and Euro

101 d-effects model with an interaction term for study group and study meal when appropriate.

102 The mean OPA in the study group and the control group were 2.01 +/- 0.69 mmH

103 m the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera International Trial, were a

104 two independent readers who were blinded to study group and the timing of the scan at a median of 6.

105 666 participants were randomly assigned to a study group and underwent transplantation.

106 s and high cost, they tend to evaluate small study groups and as a result might not provide comprehen

107 statin and antihypertensive therapy in both study groups and estimated the excess risk of stroke dea

108 No deaths were reported in any of the study groups and most reported adverse events were of mi

109 The remaining and free eyes in study groups and right eyes of control group had full op

110 anced crystalloids can produce well-balanced study groups and separation in crystalloid receipt.

111 Fifty patients with PCR-positive AK (study group) and 50 patients with bacterial, fungal, vir

112 infants born after a negative amniocentesis (study group) and those with a positive amniocentesis (co

113 ational Association of Diabetes in Pregnancy Study Groups) and large-for-gestational-age infants (>/=

114 rall survival has not been reached in either study group, and follow-up is ongoing.

115 Pfizer, International Breast Cancer Study Group, and US National Cancer Institute.

116 olites exhibited daily rhythms in at least 1 study group, and where a metabolite was rhythmic in >1 g

117 hin 90 days of LT predicted poor survival in study group as well as control groups.

118 onal childhood acute lymphoblastic leukaemia study groups assessed acute lymphoblastic leukaemia prot

119 d external examiners, blinded to the child's study group, assessed the status of the children at base

120 ICU and research staff were not masked to study group assignment during the intervention period.

121 the patients and clinicians were blinded to study group assignment.

122 vestigators and patients were unaware of the study-group assignments.

123 TMVR with the valve was feasible in a study group at high or extreme risk for conventional mit

124 did not differ significantly among the three study groups at the end of the treatment period, with me

125 Patients were randomly assigned to 1 of 2 study groups between 27 August 2013 and 28 October 2015;

126 ant or clinically important difference among study groups, but the strength of evidence was low.

127 by the International Vitreomacular Traction Study Group by 2 independent masked observers.

128 s IL-2 and IL-12 was evaluated in a separate study group by administering them with vaccine particles

129 s with access to the raw data were masked to study group by coding the groups until after the analyse

130 cologia Pediatrica, Berlin-Frankfurt-Munster Study Group, Children's Oncology Group, Dutch Childhood

131 from two randomized trials of the German CLL Study Group (CLL8: fludarabine and cyclophosphamide [FC]

132 We compared iron markers at day 0 among study groups (CM, SMA, and CC groups) and at day 28 betw

133 agement in activities did not differ between study groups (coefficient 1.44, 95% CI -1.35 to 4.24).

134 The study group comprised 114 persons with myopia (81 girls

135 The study group comprised 14 140 patients (2835 diabetics an

136 METHODS AND The study group comprised 160 patients with implantable card

137 Material/The study group consisted of 16 patients with clinical sympt

138 The study group consisted of 5 patients with and 8 patients

139 Material/The study group consisted of 60 children with T1DM, and the

140 Study groups consisted of MFG at 1 mg/kg every 24 hours

141 iteria: (1) fulfillment of the International Study Group criteria for BD; (2) clinically suggestive o

142 ic fistulas were stratified by International Study Group criteria.

143 ence rates: 79.4% in control versus 78.3% in study group (Delta=1.15%; 90% confidence interval, -10.3

144 f 2.7 years (IQR, 1.5-4.6 years) in the main study group, diabetes was diagnosed in 58 participants (

145 There were study group differences in the proportion of children wi

146 100000 person-years were determined for each study group during the 90 days after hospital discharge

147 ignificant concentration differences between study groups emphasize the importance of controlling the

148 e of Allergy and Infectious Diseases Mycoses Study Group (EORTC) definition and analyzed survival tre

149 e of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (11 probab

150 e of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus definitions (19 proven

151 the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria.

152 gal Infections Cooperative Group and Mycoses Study Group (EORTC/MSG) criteria.

153 e of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) definitions for fungal disease,

154 , the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG) proposed a conservative treatment al

155 xamined by an ophthalmologist blinded to the study group every 4 days and at the time of withdrawal f

156 ad an identical antibody profile as the main study group except they had first-phase insulin release

157 rovement was observed in the majority of the study group eyes (71%); permanent visual loss occurred i

158 The RETINODIAB (Study Group for Diabetic Retinopathy Screening) program

159 roportion of children sensitized differed by study group for four mite antigens: Dermatophagoides far

160 c Oncology and Haematology, and the Japanese Study Group for Paediatric Liver Tumours)-created a shar

161 ferences in the change over 6 months between study groups for PWT (0.9+/-0.8 minutes; 95% confidence

162 This differed between metabolite classes and study groups-for example, phospholipids showed maximal d

163 ning manual consented by a multiprofessional study group from different centers (Arbeitsgemeinschaft

164 iscovered that the association replicated in study groups from Europe and the United States (combined

165 IPI-b development (German Low-Grade Lymphoma Study Group [GLSG] 1996 and GLSG2000), we checked whethe

166 51 patients from a German Low-Grade Lymphoma Study Group [GLSG] trial and 107 patients from a populat

167 Compared with controls, the study group had a significantly shorter cryotherapy time

168 re patients in the control group than in the study group had device malfunction or device failure req

169 None of the children in the study group had neurologic sequelae at long-term follow

170 t (16.2% vs. 8.8%), and more patients in the study group had strokes (29.7% vs. 12.1%).

171 The control and study groups had similar mean number of applications per

172 nical trials within cooperative pediatric HL study groups has resulted in continued progress; however

173 nts >/=60 years of age in the German Hodgkin Study Group HD10 and HD13 trials randomized to either 2

174 azine, and prednisone) in the German Hodgkin Study Group HD12 and HD15 trials.

175 injected in right eyes of 14 rats (low dose; study group I, high dose; study group II).

176 No significant difference was found between study group (I) and control group.

177 ickened total macula, GCL, GCC, and pRNFL in study group (I) compared to study group (II).

178 detected in the control positive groups and study group (I).

179 meters compared to the control group and the study group (I).

180 a sole treatment performed earlier in life [(study group (I)], 15 unilateral RB patients who had comp

181 14 rats (low dose; study group I, high dose; study group II).

182 on and thickness of the retina especially in study group II, which also show negative VEGF immunoreac

183 CC, and pRNFL in study group (I) compared to study group (II).

184 In study group (II); a significant thinning of total macula

185 ely regressed disease with a preserved eye [(study group (II)] and 30 age and sex matched healthy con

186 for Research and Treatment of Cancer/Mycoses Study Group in 2008, we recategorized the 379 episodes o

187 hogenic dots were seen in one neonate in the study group in favour of pneumatosis intestinalis.

188 here were no significant differences between study groups in resident-reported perception of the effe

189 ons did not differ significantly between the study groups in terms of appropriateness (adjusted odds

190 There were significant differences among the study groups in terms of salivary IL-35 level (P <0.001)

191 Although no difference was observed between study groups in the number of hospital admissions at 90

192 did not differ significantly between the two study groups in the Physical Function Trial but did diff

193 e primary outcome was the difference between study groups in the proportion of isotonic crystalloid a

194 were no significant differences between the study groups in the rates of non-procedure-related strok

195 The study group included 13,089 opioid-related deaths partit

196 The final study group included 182 patients, of whom 98 (54%) were

197 The study group included 22 patients (12 men, aged 51+/-11 y

198 The study group included 61 eyes that were implanted with th

199 The study group included adolescents (N = 4612) with newly i

200 Study groups included healthy individuals with no family

201 Study groups included the recommended 1990s Pediatric va

202 In the study group, irrespective of prerevascularization severi

203 prevalence of DR in the Chinese American Eye Study Group is relatively lower than studies of Chinese

204 Between the study groups key demographic, comorbidity, clinical, and

205 In the study group, logMAR VA improved from mean 1.78 +/- 0.43

206 phrine required was no different between the study groups (mean +/- SD mug/kg; placebo + placebo grou

207 hed study data sets with 640 subjects and 14 study groups met the inclusion criteria and were include

208 At Cox proportional analysis within the study group, more than 3%, more than 5%, and more than 7

209 The end points of the study group (n = 22) were compared with those of a case-

210 The main study group (n = 389) had first-phase insulin release on

211 baseline or apnea, no wave for 10 seconds) (Study group, n = 55), or when the Observer Assessment of

212 fect plus 60- and a 120-second freeze bonus (study group, n=70).

213 e randomly allocated these villages to three study groups: no intervention (control; n=50), eight com

214 ecific total IgG1 subclass correlated in the studied group of Ebola survivors.

215 Root-feeding insects are an increasingly studied group of herbivores whose impacts on plant produ

216 ort sequence motifs, form a large but seldom-studied group of proteins.

217 This cross-sectional study comprised a study group of 30 eyes from 30 patients with NAION and a

218 enters for esophageal surgery, we selected a study group of 334 patients (31.6%) that fulfilled crite

219 d 121 live-born singletons after KT (Italian study group of kidney in pregnancy, national coverage ab

220 of enrollment to the INSPPIRE (International Study Group of Pediatric Pancreatitis: In Search for a C

221 ding to underlying heart disease, in a large study group of primary prevention patients with heart fa

222 Fungal Infections Cooperative Group/Mycoses Study Group of the National Institute of Allergy and Inf

223 ,001 patients and 287,550 controls from five study groups of European descent.

224 ndomised trial consisting of four sequential study groups of patients with stage II-III locally advan

225 s with orthotopic esophageal cancers in four study groups of six animals per group were treated with

226 e European Society for Clinical Microbiology Study Group on Legionella Infections (ESGLI), were teste

227 ing clinically significant PF (International Study Group on Pancreatic Fistula Grade B or C) and hosp

228 y endpoints were mortality and International Study Group on Pancreatic Fistula grade B/C postoperativ

229 mized to have five annual low-dose CT scans (study group) or no screening (control group).

230 ms group; insignificantly different between study groups (P = .98).

231 , 24 week relapse events were similar across study groups (p=0.44).

232 ion did not differ significantly between the study groups (P=0.97).

233 were willing to be assigned to either of the study groups, participate in all aspects of the study, a

234 Each of the study groups (patients and controls) comprised of 21 (42

235 (CLLM1; CLL Maintenance 1 of the German CLL Study Group), patients older than 18 years and diagnosed

236 underwent PV isolation with the DT catheter (study group); patients were planned for PV remapping aft

237 ll types of LTs were compared according to 4 study groups: patients transplanted between 1998 and 200

238 ll types of LTs were compared according to 4 study groups: patients transplanted between 1998 and 200

239 .797 with FABP1) and the Acute Liver Failure Study Group prognostic index (early, 0.686 alone, 0.766

240 All study groups received open-label intravenous ceftriaxone

241 linical data from the US Acute Liver Failure Study Group registry (1998-2014).

242 data in the Congenital Diaphragmatic Hernia Study Group registry between January 1, 2007, and Decemb

243 tive ALF patients from the United States ALF Study Group registry between January 1998 and December 2

244 We assessed trends for the study group relative to those for an employee group that

245 l series among different pediatric and adult study groups remains difficult; thus, initiatives to har

246 Patients with GI cancers in both study groups reported improvements in QOL and mood by we

247 s conducted at 43 US and Canadian Huntington Study Group research sites from July 9, 1999, through De

248 ed significant pancreatic volume loss in the study group (respective median pre- and posttreatment vo

249 In the study group, retromuscular mesh-augmented reinforcement

250 A pediatric pathologist, blinded to study group, reviewed biopsies for histologic abnormalit

251 ,306 patients enrolled in the German Hodgkin Study Group's fifth generation of clinical trials in HL

252 as done with the International Breast Cancer Study Group's internet-based system and was stratified b

253 striction (TAC) surgery and compared among 4 study groups: SHAM (n = 10), TAC (n = 12), MET (metoprol

254 ember 21, 2013, 37 patients at 13 Huntington Study Group sites in the United States and Australia who

255 ) in a double-blind fashion at 34 Huntington Study Group sites.

256 In the study group, SMOR detected minor resistant variant subpo

257 lability of RNAi pathways, even within well-studied groups such as Drosophila, and suggests that str

258 Attrition was lower in the ASA24/AMPM study group than in the AMPM/ASA24 group, and it was low

259 were fewer symptomatic cCMV neonates in the study group than in the control group (4.3% vs 25%; P <

260 ee survival were significantly longer in the study group than in the control group (both were 28 mont

261 of volume loss per month was greater in the study group than in the control group (reader 1: -2.1% v

262 g data from medical notes were masked to the study group the participant was allocated to.

263 r Hematology Oncology and the Nordic Myeloma Study Group (the HOVON87/NMSG18 trial).

264 In our study group, the disease predominantly affected middle a

265 In the study group, the induction time was shorter (p = 0.03) a

266 In all study groups, the SF-36 physical-component summary score

267 3-4 treatment-related adverse events between study groups; the most common grade 3-4 adverse event wa

268 In the study group, there were 32 (37%) and 54 (67%) metastatic

269 s process initiated by the International PSC Study Group to delineate appropriate candidate surrogate

270 The West German Study Group trial, ADAPT (Adjuvant Dynamic Marker-Adjust

271 ultinational Berlin-Frankfurt-Muenster (BFM) study group trial: ALL-SCT-BFM 2003 (Allogeneic Stem Cel

272 6 patients treated within the German Hodgkin Study Group trials HD7 and HD10 for early-stage favorabl

273 ents with cHL included in the German Hodgkin Study Group trials HD7 to HD12.

274 nts then remained masked in their randomised study group until the last patient enrolled completed at

275 gh week 48 (19 [2.5%] of 763 patients in the study group vs eight (2.1%) of 378 patients in the contr

276 verse events (11 [1%] of 763 patients in the study group vs four [1%] of 378 patients in the control

277 A high-risk score from the German Hodgkin Study Group was adversely prognostic for OS (P = .036),

278 The study group was compared with four control patients who

279 The study group was composed of patients diagnosed with NAIO

280 Study group was independently associated with pathologic

281 The study group was more likely to have ischemic stroke (aHR

282 Severity of PTSD symptoms across the three study groups was positively correlated with levels of ge

283 e serious adverse event (pancreatitis in the study group) was deemed as possibly related to the study

284 ed system of the International Breast Cancer Study Group, was stratified by type of previous endocrin

285 Interns were randomly assigned to 2 study groups (wCBT and attention-control group [ACG]), a

286 f the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the Lymph2Cx assay for CO

287 lts enrolled in the U.S. Acute Liver Failure Study Group were tested for anti-HEV immunoglobulin (Ig)

288 Study groups were as follows: 1) empty defect (control,

289 Study groups were as follows: 1) non-ligated control (NL

290 Both study groups were matched in clinical and laboratory dat

291 d entry criteria, no differences between the study groups were seen for change in glycated hemoglobin

292 On average, the two study groups were ventilated with well-matched strains (

293 The study groups were well-balanced at baseline: 90% were me

294 I: 3.7, 9.9 nmol/L; P < 0.0001, I(2) = 0%; 7 study groups), whereas for lean fish the mean difference

295 I: 0.6, 6.9 nmol/L; P < 0.02, I(2) = 38%; 10 study groups), whereas in long-term studies ( approximat

296 n = 277), including participants in the main study group who received oral insulin (n = 203) or place

297 es of the overall association of exposure or study group with microchimerism detection rates.

298 comparison of FMD and PISA scores among the study groups with P <0.05.

299 re was no significant difference between the study groups with regard to adverse events (including ne

300 enrolled for 89 participants (1 eye to each study group), with a total of 394 study eyes.